The list price, before insurance, will be $1,390 for a five-day course, Pfizer said in a statement. That’s 2.6 times higher than the $530-per-course price paid by the US government, which provided Paxlovid free to patients during the pandemic. The Wall Street Journal first reported the new price.
The document lays out ambitious new targets for the next five years that include reaching 90 per cent of people with TB prevention and care services, providing social benefit packages to those who have the disease, and licensing at least one new vaccine.
In the United States, a slow but steady rise in COVID activity continued over the past week according to the latest data from the Centers for Disease Control and Prevention (CDC), while at the global level, the World Health Organization (WHO) said today that indicators are up in three of six regions.
